A study of CD180 expression patterns and its signaling pathways in model cell lines of Burkitt lymphoma

Author: Ana Butkhuzi
Keywords: Burkitt lymphoma, CD180, RAMOS cell line
Annotation:

At the present stage, the subject of active research is the identification of receptors involved in oncohematological diseases and the identification of molecules, which participate in the activation of signaling pathways. These can be used as prognostic markers or/and for therapeutic purposes. One of the aggressive Non-Hodgkin’s Lymphomas is Burkitt lymphoma (BL). BL has a mature B cell phenotype. The cells express CD19, CD20, CD22, CD79a, and monoclonal surface Ig, nearly always IgM. CD5, CD23, and BCL2 are consistently negative. CD180 TOLL-like receptor is actively studied at the Department of Immunology. It is seen in B cell oncohematological diseases, such as chronic lymphocytic leukemia (CLL). CD180 is expressed in about 60% of CLL cells, which is involved in the regulation of CLL cell proliferation and apoptosis. It was interesting to study the function of CD180 in different diseases. So, for this purpose, it was used RAMOS B cell line, derived from the patient with Burkitt lymphoma. The aim of the study was to study the effect of MD1 on the level of CD180 expression in Burkitt's lymphoma model cell culture in different time point. Studies have shown that CD180 is expressed heterogeneously on the surface of RAMOS cells – approximately half of the cells in 24-hour and 48-hour cell cultures are positive for CD180. And, MD1 is a positive regulator of the CD180 receptor.